objeCtives: Clinical researches are an important tool for the improvement of medicine and significant economic value. The aim of this study was to investigate the economic impact of clinical researches to the research centers and reimbursement system in Turkey. Methods: Budget of clinical trials were calculated from the raw data of the Report of Istanbul Medical Faculty Clinical Researches (ITFKAR) between years 2006-2010. In addition, the possible cost of the drugs that were used in the clinical researches for SGK was calculated for showing the cost of medicines acquired with clinical researches. It has been accepted that predicted budgets of reviewed files were spent for research. Similarly, it has been accepted that the number of patients was not changed during the studies. Thus, approved budgets could be accepted as drug investment of the approval year. For the calculation of drug costs, discounted reimbursement figures of Social Security Administration (SGK) for licenced products were used. If not licenced and imported via Turkish Chamber of Pharmacists, the prices of abroad drug list of SGK were used. Calculations were performed with the drug prices for the year 2013. Results: The average of drug cost savings per patient with participation to the clinical research and clinical research investment per patient were calculated as US$ 21.649 and US$ 4.879. It could be said that total budget of sponsored pharmaceutical researches was US$107 million and the government had a saving close to US$ 311.096.130 due to not reimbursing the cost of drugs of the patients who were included to the clinical researches in Turkey depending on the analysis. ConClusions: However study is based on assumptions, the findings are unique for the literature. The health policy makers can take account the study of the policy improvements about clinical trials in Turkey. objeCtives: In 2011 the budget of the public payer in Poland, National Health Fund (NHF) amounted to 58.2 bln PLN. 47.3% of these funds was allocated to fund hospital treatment which is based on diagnosis-related groups (DRGs) but also includes innovative, expensive drugs (i. a. chemotherapy, orphan). The aim of the paper was to identify the existing correlation between hospital morbidity and the average unit cost of hospital treatment in various chronic diseases. Comparison of individual hospital costs of treatment different chronic diseases with varying degrees of severity, different course and level of incidence (from common to ultrarare) open the possibility of presenting the correlation between morbidity and unitary medical costs incurred by the NHF for the treatment of various indications. Methods: The analysis was prepared for 23 therapeutic areas, which were divided into 4 categories (diseases: common, infectious, pediatric and rare /ultrarare), diversified both in terms of severity and morbidity. This choice gave a possibility of comparing a wide range of chronic diseases, which have a significant impact on quality of life and mortality. The analyzed material included hospital procedures and services indicated by the NHF in 2011. Results: Using the Pearson's linear Correlation test, dependence between variables (the average cost of hospitalization and the number of patients) for 23 therapeutic areas was assessed. The results showed that the lower prevalence (fewer patients with the diagnosis) is connected with the higher average unit cost of treatment. ConClusions: In Poland, among all studied diseases the most expensive was the individual treatment of patients diagnosed with ultrarare diseases (i. a. Lysosomal storage diseases). Chronic ischemic heart disease, hypertension and diabetes mellitus were associated with the largest number of annual hospitalizations and globally were the most cost-intensive for NHF. At the same time hypertension is associated with the lowest average unit cost of hospitalization among all studied diseases. objeCtives: Payers all need evidence of clinical effectiveness, reasonable cost, and safety. Although, patient-reported outcomes (PROs) are an important component of this evidence it is not always clear which PROs to use and reliance on an incorrect PRO can have negative consequences. The objective was to describe the factors determining which PROs are most likely to meet payer evidence needs. Methods: A structured discussion of factors influencing PRO choice was held between experts in late phase studies, evidence review, and economic modelling. These were then validated against a sample of published reimbursement decisions across multiple disease areas. Results: Focus of most questions is on whether to use a generic, disease-specific or novel measure. Disease specific PROs are very frequently of value in demonstrating clinical effectiveness and may be the standard clinical outcome. For example, migraine studies include pain assessment and headache frequency. To facilitate Payers' decision making generic PROs such as EQ-5D and SF-36 are commonly used for assessing quality of life (QoL). However these instruments may not be reliable in disease areas characterised by focal impacts on patient wellbeing. For example, pain is only a small component of the SF-36 consequently changes in pain levels cannot be measured with great precision and the extreme effects of pain may be missed when generating estimates of utility. ConClusions: When choosing a PRO, it is important to consider the disease, treatment and payer reimbursement decision context. Disease specific QoL measures may be more sensitive than a generic tool but may also need mapping to a general QoL measure. Acceptance will be contingent on the existence of robust evidence either from published literature or additionally collected data. Reviews of previous HTA submissions and payer decisions help identify requirements / standard practices in key markets and identify common criticisms or problems. objeCtives: Greece is under a very tough and strict memorandum enforced by the European Union that has designed and applied austerity measures in order to save Greek economy and minimizes its public debt. Also the Greek Heath care system should be improved, upgraded or redesigned from scratch in order to be more flexible and more efficient. the treatment of asthma were not accepted due to comments about population and model input, lack of statistical calculations and size of the incremental effects. Ranibizumab's results for age-related macular degeneration were not accepted because of a wrong comparator, lack of long term data, assumptions on risks and mortality, and uncertainties around health care costs and ICER sensitivity. Finally, ZiNL considered the appropriate use of alglucosidase alfa for Pompe's disease to be unsubstantiated because of the population choice for the ICER calculation and the use of a higher dose than the registered dose which was not supported by scientific data. The outcome results of alglucosidase alfa for cost-effectiveness were accepted, however. ConClusions: Although at T= 0 ZiNL provided feedback regarding the design of the outcome research study, most of ZiNL's comments were on the final methodology used. The outcome research studies were considered to be of mixed quality and the results could often not substantiate the claim of cost-effectiveness and appropriate use. objeCtives: In the UK, when a technology is recommended by the National Institute for Health and Care Excellence (NICE), the NHS is mandated to provide the funding to accommodate it within three months. Explicit in NICE's approach to health technology assessment (HTA) is the assumption that the approval of a new, cost-increasing technology will result in the displacement of an existing, less cost-effective health care programme from elsewhere in the NHS. The objective of this study is to identify the actual opportunity costs of specific NICE decisions by documenting how in practice local commissioners in Wales accommodated financial shocks arising from technology appraisals (TAs). Methods: Interviews were conducted with Finance and Medical Directors from all seven Local Health Boards (LHBs) in NHS Wales. These interviews covered prioritisation processes, as well as methods of financing NICE TAs and other financial "shocks" at each LHB. We then undertook a systematic identification of themes and topics from the information recorded. Results: The financial impact of NICE TAs is generally planned for in advance and the majority of LHBs have contingency funds available for this purpose. Efficiency savings (defined as reductions in costs with no assumed reductions in quality) were a major source of funds for all cost pressures. Service displacements were not linkable to particular TAs and there appears to be a general lack of explicit prioritisation activities. The Welsh Government has, on occasion, acted as the funder of last resort. ConClusions: The assumption that newly recommended technologies will displace existing NHS services does not appear to hold true in practice. As the additional cost pressures represented by new NICE TAs are likely to be accommodated by greater efficiency and increased expenditure, the true opportunity cost of HTA decisions is extremely difficult to quantify and may even lie outside the NHS. objeCtives: Western countries health care systems face growing challenges dealing with disability and death due to chronic diseases. Coordination of health care services has become unavoidable. Our objective was to identify the Integrated Health Services (IHS) in the major health care markets and understand the funding process. Methods: IHS provided in Europe, North America and Asia were identified through a literature review. Future perspectives were based on country policy and observed trends. Results: All studied countries developed IHS such as disease management, case management and telemonitoring services, with the United States (US) being the major market. However, levels of implementation, funding processes and stakeholders involved vary highly between different countries. Funding processes such as fee for services and capitation are widely used in all studied countries and Payment for performance (P4P), bundled payment and diagnosis-related group (DRG) for outpatient are in progress, used mainly in the US, and to a much lower extent in the United Kingdom (UK) and Germany. Multiple IHS exists in France, though inappropriate incentives hinder their development. In the US, under the Affordable Care Act, Accountable Care Organisations (ACOs) are testing a range of payment models (capitation, one-sided/two-sided shared saving fee-for-service, bundled/episode payments and P4P). ConClusions: IHS have become ubiquitous in all health organisations. All countries studied are expected to develop more IHS based on P4P schemes. The P4P of ACOs represents the ultimate gold mine for the development of paid health care services. Even if this concept is still in progress it will be leading this market. This will also change dramatically the way pharmaceutical companies will do business. Drugs will have to be integrated in a more complex selling process driven by medium to long term outcome impact. The management of confounding factors on outcomes is critical and represents the challenge for ACOs.
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Leppert F. , Dockweiler C. , Eggers N. , Webel K. , Hornberg C. , Greiner W. Bielefeld University, Bielefeld, Germany objeCtives: The comprehensive implementation of telemedical applications still lags behind expectations in Germany. One of the main barriers to innovation is a lack of both a willingness to adapt and user's acceptance. Processes of adoption and acceptance are characterized by a network of different factors which influence attitude and behavior which differ in severity depending on each user group. One key factor for accepting and adopting an innovation is the economic framework. We therefore examined the influence of economic factors influencing the Senegal, Egypt, Morocco, Algeria and Tunisia) are contributing # 80% of the pharma market in Africa. Despite maintaining regional offices within Africa, many major Pharma and device manufacturers frequently overlook the continent when sponsoring clinical studies. Cultural barriers, political upheaval and uneven infrastructure are certainly causes for the lack of interest. But Africa offers tremendous expertise and opportunity for drug and device companies looking for cost-effective study sites and appropriate patient drug market populations. Currently more than 45% of the whole continent's clinical trials are being conducted in South Africa and hence the need for the next generation clinical trial destination for a drug and device manufacturers. These companies can also consider technology transfer by partnering with local drug manufacturers and research centers to diversify their business portfolio. ConClusions: Africa presents real opportunities that should encourage many pharmaceutical companies to really engage in innovative clinical research programs in a win-win approach.
PHP106 market analysis in regarD to biologically active suPPlements anD meDicines in armenia
Beglaryan M. , Amirjanyan A. Yerevan State Medical University, YEREVAN, Armenia objeCtives: Although, whether biologically active supplements (BAS) are medicines or not is still debatable, BAS keep making their way to the customer basically through pharmacies. A worldwide tendency toward "greener" choices when purchasing health status modifiers (HSM) is well documented. Current endeavor studies the pharmaceutical market situation (PMS) in Armenia (2009 to 2013) in regard to growth trends both in US dollars turnover (USDT) and number of packs sold (NPS) of BAS versus medicines, stratified by five leading diseases (LD). Methods: Statistical data on morbidity and mortality from the MOH RA were used to identify the leading five disease groups in newly identified cases. Further, statistical data on pharmaceutical market from "Pharmexpert" Marketing Research Centre (analysis of wholesale sales volumes to the retail drug stores) were investigated to identify growth rate (GR) trends of interest. Results: A PMS analysis has shown 11.92% and 6.65% of GR (medicines and BAS combined) in USDT and NPS respectively. For medicines alone the results were: 11.56% and 6.23% GR in USDT and NPS respectively. As for BAS, USDT and NPS, the figures were 21.48% and 15.36% of GR respectively. A further stratification by five LM has shown the highest GR in medicines used for treatment of Uro-Genital diseases (13.24% and 10.01% for USDT and NPS respectively), whereas in BAS the highest GR was in the Cardio-Vascular group (63.84% and 92.82% for USDT and NPS respectively). ConClusions: The results of the study go in line with the worldwide trends in shifting whenever possible, from medicines to using HSM of natural origin, of which BAS are a major part. The study does not claim to identify the underlying compound factors influencing such a tendency. However, the reality at had compels for studying the levels of BAS administration and use literacy among both HSM prescribers and consumers. objeCtives: This study seeks to evaluate the incremental benefit scores granted to new medicines under the 2011 AMNOG reform in Germany, and if there is a correlation between that score and the extent of price reduction after negotiation with the statutory health insurance fund. Methods: Resolutions issued by the G-BA related to all drugs which achieved the early benefit assessment process between January 2011 and June 2014 were reviewed to determine whether the drugs were deemed to bring an added benefit. Under AMNOG, an added therapeutic benefit score is granted to medicines according to 6 categories (major, considerable, minor, non-quantifiable, no or less added benefit versus the comparator). As part of the study, IHS created an overall quantitative innovation score for each product, based on any and all qualitative ratings granted by the G-BA in each patient subgroup. The score ranged from 0 (no added benefit proven) to 4 (major added benefit) and was weighted against each patient population. An average price reduction per innovation score range was then calculated. Results: Out of the 76 drugs assessed in the study, a total of 44 were deemed to bring an added benefit over the appropriate comparator by the G-BA, of which 34 had achieved price negotiation as of end of May 2014. These ratings translated into an average innovation score of 1.77, and were subject to price cuts averaging 21.7%. ConClusions: Our analysis highlights that innovative medicines can be subject to significant price cuts in Germany. No correlation between the innovation score and subsequent price cuts could be derived, as many other factors, including the initial price difference between the new medicine and the comparator, enter into account as part of the price negotiations.
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Lie X. , Nijhuis T. Quintiles Consulting, Hoofddorp, The Netherlands objeCtives: If the cost-effectiveness and appropriate use of a drug in the Netherlands cannot yet be determined during the initial reimbursement assessment (T= 0), this will be done at the re-evaluation 4 years later (T= 4) using RWD. Outcome research is an essential part of the re-evaluation of conditionally reimbursed drugs. The objective was to assess the reasons for accepting or rejecting outcome research results to confirm cost-effectiveness and appropriate use of a drug at T= 4. Methods: The website of Zorginstituut Nederland (ZiNL) was searched for re-evaluations of drugs published between January 2006 and May 2014. ZiNL's assessments of the outcome research were compared. Results: ZiNL published the outcome research results for four drugs. The outcome research results for agalsidase alfa & beta were accepted for demonstrating cost-effectiveness and appropriate use in Fabry's disease. The T= 4 results for omalizumab for
